C4 Therapeutics (CCCC)
US Market

C4 Therapeutics (CCCC) Income Statement


C4 Therapeutics Income Statement

Last quarter (Q2 2023), C4 Therapeutics's total revenue was $2.66M, a decrease of -80.74% from the same quarter last year. In Q2, C4 Therapeutics's net income was $-35.92M. See C4 Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 13.18M$ 31.10M$ 45.78M$ 33.20M$ 21.38M$ 19.36M
Cost of Revenue
Gross Profit
$ 6.42M$ 31.10M$ 45.78M---
Operating Expense
$ 119.46M$ -160.63M$ -127.92M$ 93.64M$ 56.83M$ 35.75M
Operating Income
$ -106.28M$ -129.53M$ -82.13M$ -60.45M$ -35.45M$ -16.39M
Net Non Operating Interest Income Expense
$ 4.22M$ 1.36M$ -1.76M$ -836.00K$ 2.16M$ 685.00K
Other Income Expense
$ -1.76M$ 3.36M$ 788.00K$ -5.68M$ 325.00K$ -7.00K
Pretax Income
$ -100.30M$ -131.54M$ -84.68M$ -66.96M$ -33.30M$ -15.71M
Tax Provision
---$ -626.00K$ 804.00K$ 0.00
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -100.99M$ -131.54M$ -84.68M$ -66.33M$ -34.10M$ -24.11M
Basic EPS
$ -2.09$ -2.62$ -1.82$ -5.83$ -2.31$ -1.63
Diluted EPS
$ -2.09$ -2.62$ -1.82$ -5.83$ -2.31$ -1.63
Basic Average Shares
$ 147.02M$ 48.86M$ 46.04M$ 11.37M$ 14.79M$ 14.79M
Diluted Average Shares
$ 147.02M$ 48.86M$ 46.04M$ 11.37M$ 14.79M$ 14.79M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ -160.65M$ 160.63M$ -127.92M$ 93.64M$ 56.83M$ 35.75M
Net Income From Continuing And Discontinued Operation
$ -102.66M$ -131.54M$ -84.68M$ -66.33M$ -34.10M$ -15.71M
Normalized Income
$ -59.79M--$ -60.71M$ -34.10M$ -15.71M
Interest Expense
$ 554.00K--$ 1.23M$ 0.00-
$ -101.19M$ -131.54M$ -82.92M$ -65.73M$ -33.30M$ -16.39M
$ -98.77M$ -122.54M$ -77.42M$ -64.11M$ -31.70M$ -15.12M
Currency in USD

C4 Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis